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Abstract. Mass drug administration (MDA) was a component of many malaria programs during the eradication era,
but later was seldomly deployed due to concerns regarding efficacy and feasibility and fear of accelerating drug
resistance. Recently, however, there has been renewed interest in the role of MDA as an elimination tool. Following a
2013 Cochrane Review that focused on the quantitative effects of malaria MDA, we have conducted a systematic,
qualitative review of published, unpublished, and gray literature documenting past MDA experiences. We have also
consulted with field experts, using their historical experience to provide an informed, contextual perspective on the role
of MDA in malaria elimination. Substantial knowledge gaps remain and more research is necessary, particularly on
optimal target population size, methods to improve coverage, and primaquine safety. Despite these gaps, MDA has
been used successfully to control and eliminate Plasmodium falciparum and P. vivax malaria in the past, and should
be considered as part of a comprehensive malaria elimination strategy in specific settings.
INTRODUCTION
Mass drug administration (MDA) was a component of
many malaria elimination programs during the mid-twentieth
century eradication era, but since then the malaria community
has viewed it with skepticism due to concerns regarding its
efficacy, sustainability, and operational feasibility, a lack of
clear objectives for MDA programs, and fear of accelerating
drug resistance.1 However, in light of the availability of anti-
malarials with transmission-reducing effects (e.g., artemisinin-
based combination therapies [ACTs] and primaquine) and the
limitations of current diagnostic tools to detect sub-patent
infections, the role of MDA as an elimination tool needs
to be reexamined.2,3 Many field studies and programmatic
implementations of MDA have been carried out over the
past century with varying degrees of success. An initial
review of this heterogeneous body of work was conducted
in 2003,4 and a Cochrane Review focusing on the quantita-
tive effects of malaria MDA was published in December
2013.5 To build on these reviews and maximize understand-
ing of the key factors for success in previous MDA campaigns,
we have conducted a qualitative analysis of published, unpub-
lished, and gray literature, supplemented with consultations
with malaria MDA experts. A summary of our primary find-
ings and the remaining knowledge gaps are presented here,
to serve as the basis for improved design and implementation
of MDA in malaria elimination and eradication programs.
METHODS
We conducted a comprehensive literature review and held
consultations with experts to thoroughly document current
and past experiences with MDA. The literature search origi-
nated from the Cochrane Review,5 in which 3,048 studies
were identified for screening. We assessed 240 of these studies,
applying several exclusion criteria (see Appendices A and B).
We included a wide range of chemoprevention studies of
varying quality with the aim of obtaining essential information
on operational details and other study features that were
excluded from the Cochrane Review. Thus, studies that treated
subgroups rather than entire populations as well as those that
used subtherapeutic drug doses were included. Data from all
included studies were systematically extracted and entered into
a Qualtrics (Qualtrics, Provo, UT) database for analysis.6
We identified experts with experience in conducting MDA
for malaria and other vector-borne diseases through pub-
lished literature and recommendations from colleagues. Input
was solicited from any experts interested in participating,
regardless of when or where their MDA experience occurred,
the outcomes of their fieldwork, or opinions on MDA. Efforts
were made to interview experts with experience in a wide
range of geographical and endemicity settings. Individual
consultations were conducted in person, by telephone, or by
e-mail using a semi-structured questionnaire that covered pri-
mary MDA topic areas to guide the discussion, and included
requests for any unpublished reports and gray literature that
experts were willing to share.
RESULTS
After applying the exclusion criteria described in the
appendices and dividing some studies into sub-studies to
facilitate data extraction, we analyzed a total of 182 pub-
lished accounts of MDA. These studies were carried out all
over the world and span the whole of the past century, with
the earliest published in 1913 and the most recent in 2011.
Several reports were obtained through expert consultations,
documenting the implementation of MDA campaigns in the
field that had not been published in English language aca-
demic journals. These unpublished reports included cam-
paigns that took place in Nissan, Papua New Guinea in the
1960s,7 the Solomon Islands in the late 1980s, and Comoros
in the mid-2000s. Additional reports documenting work in
Afghanistan, Azerbaijan, Democratic People’s Republic of
Korea (DPRK), Tajikistan, and China have since been pub-
lished.8,9 In addition to this documented work, the 15 MDA
experts shared personal experiences with implementing MDA
for malaria and other vector-borne diseases in Africa (Burkina
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Faso, Ethiopia, The Gambia, Liberia, Nigeria, and Senegal),
Asia Pacific (Greater Mekong subregion and Vanuatu), and
the Americas (Ecuador and Guatemala). Nonresponses to
consultation requests led to under-representation from the
Americas and eastern Mediterranean regions.
The data extracted from the literature review, unpublished/
gray literature, and qualitative consultations were analyzed
by topic, including operational details, contextual character-
istics, and drug regimen.10 As established in the Cochrane
Review, the studies varied considerably in terms of design,
rigor, and depth and quality of data, limiting their analysis
and comparability. Qualitative data obtained through expert
consultations were therefore essential to gain a more com-
prehensive understanding of past MDA experiences and
provide important contextual background for the findings of
the review.
Characteristics of successful studies. Many of the published
studies were deemed successful by the investigators, although
most did not define their objectives clearly, making it difficult
to assess whether study goals were actually achieved. Despite
this lack of clarity, we identified 12 studies that met a defini-
tion of success applicable to malaria elimination settings: zero
indigenous malaria cases in the target population maintained
for at least 6 months after the end of all drug administration
(Table 1). The majority of the published studies (63%) had
a follow-up period of less than 6 months, preventing an
assessment of the interventions’ long-term effects on trans-
mission. Many studies were able to reduce parasite preva-
lence in the target population temporarily, but either were
not able to reach zero prevalence or were followed by an
increase in prevalence shortly after drug administration ceased,
a finding echoed in the Cochrane Review.5
The primary factors determining the success of MDA
mentioned almost universally by MDA experts were: achiev-
ing at least 80% or even 90% coverage of the target popu-
lation with drug administration, directly observed treatment
(DOT), strong community engagement, high coverage with
concomitant vector control interventions, and the use of
8-aminoquinolines, particularly in Plasmodium vivax trans-
mission settings.
Delivery methods and community engagement. The pub-
lished studies did not thoroughly or consistently explain their
delivery and community engagement strategies, but those
that did used a wide range of approaches. In the studies that
involved DOT (58%), drug distribution and observation was
performed by community volunteers, local health workers,
study authors, and/or external organizations. DOT was not
limited to small-scale MDA; while most studies targeted
populations in the hundreds or thousands, several campaigns
implemented DOT among populations in the hundreds of
thousands and even millions. Table 2 summarizes the MDA
campaigns that were conducted on a large scale, covering
100,000 people or more. In addition, DOT has been imple-
mented not just for single-dose treatment but also for com-
plicated, multiday drug regimens. For example, in Palestine,
a population of 1,257 villagers was treated twice daily for
5 days over three monthly rounds.11 Through DOT, mainte-
nance of treatment lists, and careful follow-up, study authors
were able to treat 81% of the population with all three
rounds of MDA. The number of rounds of drug administra-
tion varied widely among the successful studies, from just
one to numerous rounds distributed over 2 months to 10 years.
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128 NEWBY AND OTHERS
Other strategies leading to effective MDA included popu-
lation censuses and the mobilization of local workers to
monitor the movement of people in and out of a study area.
One study described the use of incentives for community par-
ticipation and adherence to the full MDA regimen, specifically
lottery tickets for prizes (sewing machines, bicycles, etc.).12 Six
of the 12 successful studies used DOT with trained volunteers
or the study authors themselves, whereas delivery methods in
the other studies were not described. Different types of com-
munity engagement were used in the successful studies, namely,
working with community leaders and elders to ensure coopera-
tion, extensive health education and outreach, and active par-
ticipation through the formation of volunteer malaria teams.
Two study authors specifically noted that strong community
participation was crucial for success.13,14
MDA experts stated that delivery methods involving
house-to-house visits are preferred over distribution at cen-
tralized, fixed-point locations when logistically feasible, to
ensure high coverage. Local health workers or volunteers
should be used for drug distribution, since they understand
the environment and local customs, and can garner more trust
and acceptance among their peers than outsiders. In areas
with low transmission, experts recommended working with
older members of the community who may remember when
malaria was more prevalent and be more committed to pre-
venting its return.
The unpublished account of MDA in the Solomon Islands
is a prime example of the importance of securing community
buy-in to achieve high coverage. This project targeted a popu-
lation of around 30,000 in the capital city and was thoroughly
planned, well staffed with local workers, and involved mass
media community outreach to encourage participation, yet
coverage was still only 67%. Investigators believed that this
was due to refusal of the targeted population to take multiple
rounds of drugs when they were not ill. In comparison, the
MDA carried out in Nissan, Papua New Guinea was notable
for achieving nearly 100% coverage, attributed by the inves-
tigators to a high degree of community cooperation and a
strong health infrastructure that facilitated intense screening
of all arrivals to the island.7
Co-interventions. Co-interventions were deployed in nearly
half of the studies. Of these, 65% conducted indoor residual
spraying (IRS), primarily using dichlorodiphenyltrichloroethane
(DDT), 33% conducted chemical or biological larval control,
23% carried out environmental management (e.g., vegetation
clearing, waterway construction), and 16% distributed bed nets,
treated or untreated. Ten of the 12 successful studies imple-
mented vector control co-interventions: eight used IRS, three
used insecticide-treated nets, and two used multiple measures.
Experts agreed that vector control is essential and should be
used prior to commencement of, or concurrently with, MDA
to bring transmission down to low levels.
8-aminoquinoline-based drug regimens.Drug regimens used
in the published studies were diverse, and varied depending
on location and timeframe as well as on biological concerns,
including those related to the prevalence of glucose-6-
phosphate dehydrogenase (G6PD) deficiency. 8-aminoquinolines
were included in 69 of the studies (38%), five of which were
monotherapies with either plasmoquine or primaquine. Six of
the 12 successful studies included 8-aminoquinolines in com-
bination with other drugs. All but one of the unpublished
reports included primaquine, distributed as monotherapy
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Table 3
Examples of primaquine-containing MDA drug regimens
Study author
Country
Years Drug regimen G6PD considerations Adverse events Outcomes at conclusion of intervention
Primaquine to target P. vivax malaria (hypnozoites)
Singh30
India
1962–1964
Total PQ dose = 75 mg G6PD-deficient
patients treated
None reported Pv transmission suppressed during
study period; incidence decreased
from 0.98 to 0.006 cases/1,000
persons/month, maintained over
one year
PQ 15 mg/day for 5 days +
CQ 600 mg single dose for
four rounds; first round
treated everyone;
subsequent rounds
targeted only febrile cases
and their contacts
WHO7
Nissan,
Papua New
Guinea
1962
Total PQ dose = 360–720 mg G6PD-deficient
patients
treated; GdA−1
deficiency
prevalence on
Nissan = 30%
Hemoglobin levels in deficient
patients checked weekly;
weeks 1 and 2 did not drop
below 2 g%, rose by week 3;
at end of 8 weeks, about
1 g% higher than at start
of MDA
Pf eliminated from Nissan; Pv
reduced to low level but not
eliminated due to presence of
PQ-tolerant Chesson-like strains
PQ 45–60 mg given by local
residents as DOT weekly
for 8–12 weeks
Kondrashin8
Afghanistan,
Azerbaijan,
DPRK, Tajikistan
1971–2007
Total PQ dose = 210 mg G6PD-deficient
patients treated,
with close
monitoring
Severe side effects related to
G6PD deficiency (i.e., red
or black urine) did not
exceed 1%; minor side
effects did not exceed 4%
Considerably reduced Pv malaria
where alternate forms of malaria
control were unavailable
PQ 15 mg given as DOT
daily for 14 days in
seasonal settings, either
before or after
transmission season
Hsiang9
China
1973–1983
Total PQ dose = 180 mg G6PD-deficient
patients treated
Not systematically monitored;
49 cases of acute hemolysis
reported in five studies that
identified severe adverse
events in deficient patients
Seasonal MDA administered to
almost 30 million people,
malaria incidence decreased by
56.7% (1973–1976) and by
12.4% (1976–1983)
PQ 22.5 mg daily for 8 days
and PYR 50 mg daily for
2 days administered to
entire villages in the
spring, prior to
transmission season
Liu19
China
1981–1985
Total PQ dose = 180 mg G6PD-deficient
patients treated
None reported Incidence of Pv decreased;
prevalence maintained at 0%
for three years of post-MDA
follow-up
During low transmission
season: CQ 1,200 mg
total + PQ 180 mg total
over 8 days;
During high transmission
season: CQ 300 mg + PQ
30 mg twice per month
Kaneko14
Aneityum,
Vanuatu
1991
Total PQ dose = 360 mg G6PD-deficiency
not detected on
Aneityum
None reported Sustained interruption of
malaria transmissionCQ 600 mg + SP 1,500 mg/
75 mg + PQ 45 mg once in
weeks 1, 5, 9; CQ 300 mg +
PQ 45 mg once in weeks
2–4 and 6–8
Hsiang9
China
2000–2009
Total PQ dose = 180 mg G6PD-deficient
patients treated
Five subjects in 2003 and two
in 2007; some experienced
hemolysis
Malaria incidence decreased by
14–44% in the two counties
where MDA was conducted
CQ 400 mg daily for 3 days +
PQ 22.5 mg daily for
8 days, targeted to
household members and
neighbors of index cases
in the spring
Primaquine to target P. falciparum malaria (gametocytes)
Hii38
Malaysia
1984–1985
Total PQ dose = 60 mg G6PD-deficient
patients treated
None reported Pf prevalence temporarily decreased
for 2 months after intervention;
Pv prevalence did not change
SP 1,430–70 mg + PQ 30 mg
once per month for
2 months
Doi39
Indonesia
1987–1989
Total PQ dose = 84–120 mg
SP 25–30 mg/kg -
1.25–1.5 mg/kg single
dose + PQ 0.7–1.0 mg/kg
once per week for 2 weeks
G6PD-deficient
patients treated
None reported Pf prevalence declined from 14% to
1% eight months after MDA
Song13
Cambodia
2003–2004
Total PQ dose = 162 mg G6PD-deficient
patients treated
None reported Parasite prevalence rate declined
from 52.3% to 2.6% after 3 yearsArtemisinin 125 mg + PIP
750 mg daily for 2 days +
PQ 9 mg every 10 days
for 6 months
(continued)
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or in combination with artemisinin derivatives and other
blood schizonticides. 8-aminoquinolines were used for both
P. falciparum and P. vivax MDA programs, although exact
regimens varied according to targeted species. A selection of
primaquine-containing dosing regimens is shown in Table 3.
Only eight studies that included 8-aminoquinolines docu-
mented the prevalence of G6PD deficiency in the target
population (ranging from 1% to 39%), and just three of those
studies documented drug safety protocols. For example, in
China and DPRK, patients with a history of hemolysis were
excluded from future treatments, whereas in Afghanistan and
Azerbaijan, a modified drug regimen was implemented in
which the 14-day course of primaquine treatment was inter-
rupted and drugs were not given on days 5–7. Because this
intermittent schedule was thought to disrupt the hemolytic
effects of the drug, it was deemed safe for populations with
a high prevalence of G6PD deficiency.8 Regardless of drug and
dosing regimen, no MDA-related deaths were documented
during these primaquine-based campaigns; patients who
experienced adverse events recovered with routine supportive
care, and no long-term hospitalization or blood transfusions
were necessary, according to investigators’ records. How-
ever, it should be noted that none of these studies reported
using an active pharmacovigilance system.
Few studies included details on subpopulations excluded
from MDA for safety reasons. When they were described,
the most common excluded groups were infants and young
children. Other excluded groups, described infrequently,
included pregnant women, subjects recently treated for
malaria, and people with chronic illness. Fewer than 10% of
the studies that included 8-aminoquinolines explicitly noted
the exclusion of pregnant women; none of the studies
reviewed reported on pregnancy outcomes when discussing
adverse events.
MDA experts universally believed that inclusion of an
8-aminoquinoline in the drug regimen, either primaquine
or tafenoquine, was essential for eliminating the last reser-
voirs of infection. They noted that patient monitoring is
critical for quickly identifying subjects with hemolysis, and
medical interventions, including blood transfusion, should
be readily accessible.
P. vivax elimination. A primary finding of the Cochrane
Review was that MDA had a greater impact on P. falciparum
transmission than on that of P. vivax in a given study using
the same drug regimens, which did not always include
an 8-aminoquinoline. Our qualitative analysis of a much
broader range of MDA campaigns than that covered by the
Cochrane Review reveals strong evidence that MDA with
an 8-aminoquinoline is an effective intervention against
P. vivax, particularly as an outbreak response in highly sea-
sonal transmission settings. The study carried out in Jiangsu
Province, China in the 1970s describes the use of primaquine
to reduce P. vivax transmission on a massive scale.9 Entire
counties, nearly 30 million people in total, were given directly
observed, seasonal “spring treatment” by teams of community
health workers and local public health officers prior to the
onset of the transmission season, largely in the absence of
vector control measures. According to the few records avail-
able, the incidence of severe adverse events was negligible
and no deaths were reported, despite the enormous scope
of primaquine distribution. After 10 years of MDA, the
annual parasite index of P. vivax in Jiangsu Province dropped
from 113.6 to 2.1 per 1,000 population.
Other examples of successful control of P. vivax epi-
demics with primaquine-based MDA are found in the series
of recently published accounts from Afghanistan, Azerbaijan,
DPRK, and Tajikistan.8 In these countries, an approach called
mass primaquine prophylactic treatment (MPPT) was used,
consisting of closely monitored 14-day courses of primaquine
as monotherapy on an annual basis, ranging from three to
13 rounds. As in Jiangsu Province, reports of adverse events
were rare: across all locations and years, less than 4% of
nearly 9 million people treated experienced adverse events,
with no blood transfusions reported. Unlike the Jiangsu
account, vector control interventions were emphasized as
important for the success of MPPT. However, due to a lack
of resources, vector control activities in some areas were
often of poor quality and achieved only minimal coverage,
according to the investigators. Despite these problems, con-
siderable case reductions and halting of P. vivax epidemics
were seen in Afghanistan, Azerbaijan, and DPRK, all of
which were able to achieve drug coverage of over 90% in
populations ranging from 24,000 to 500,000. In Tajikistan,
the effects of MPPT were not as pronounced, and this was
attributed by the study authors to the fact that population
coverage never exceeded 80%.
TABLE 3
Continued
Study author
Country
Years Drug regimen G6PD considerations Adverse events Outcomes at conclusion of intervention
Li (unpublished)
Moheli Island,
Comoros
2007
Total PQ dose = 108 mg G6PD-deficient
patients treated
None reported Parasite prevalence rate declined
from 21.6% to 0.86% after
18 months
Artemisinin 125 mg + PIP
750 mg daily for 2 days, in
2 monthly rounds + PQ
9 mg every 10 days for
4 months
Mahidol-Oxford
Research Unit
Protocol40
Cambodia
2013–2014
Total PQ dose = 45 mg G6PD-deficient
patients treated
Results not yet available Results not yet available
DHA 40 mg + PIP 320 mg
daily as DOT for 3 days +
PQ 0.25 mg/kg on day 1;
regimen given monthly
for 3 months
CQ = chloroquine; DHA = dihydroartemisinin; DOT = directly observed treatment; G6PD = glucose-6-phosphate dehydrogenase; MDA =mass drug administration; MPPT =mass primaquine
prophylactic treatment; Pf = Plasmodium falciparum; PIP = piperaquine; PQ = primaquine; Pv = Plasmodium vivax; PYR = pyrimethamine; SP = sulfadoxine-pyrimethamine.
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DISCUSSION
This extensive review of published, unpublished, and gray
literature has revealed a wealth of information supporting
the use of MDA as an intervention for malaria elimination.
Selected points summarized here address key factors for suc-
cessful design and implementation of MDA, and highlight
important gaps in knowledge that need to be addressed to
move toward broader implementation of MDA as part of
malaria elimination programs.
Our review has shown that in the majority of previous
studies, MDA reduced parasite prevalence (or other mea-
sures of transmission) only temporarily, and transmission
returned to pre-intervention levels shortly after drug adminis-
tration concluded. In these settings, this occurred even after
multiple rounds of MDA were combined with vector control
or included an 8-aminoquinoline. However, we also identified
several examples in which MDA interrupted malaria transmis-
sion. In general, we found that implementing MDA in higher
endemicity settings will reduce transmission, but there is a
much better chance of interrupting transmission when MDA
is implemented in areas of low endemicity in combination with
other interventions, findings that were echoed in the Cochrane
Review. Malaria was successfully eliminated from Aneityum,14
Lanyu,15 and Nissan,7 small island settings where ports of entry
were controlled and population movement was closely moni-
tored. Similar success was seen in village settings that were
relatively remote, geographically.13,16,17 Yet achieving elimina-
tion was not limited to small, isolated populations. Transmis-
sion was sometimes interrupted even when much larger groups
were targeted with MDA,18–21 indicating that delivery strate-
gies and intervention combinations may be more critical deter-
minants of success than population size.
An additional factor favoring success is an ability to adapt
an MDA strategy to changing circumstances. This was dem-
onstrated in Cambodia, where it was observed that parasite
rates persisted in some villages after receiving MDA.13 In
response, investigators revised their study protocol, adding a
second round of treatment in those villages, and replacing
local malaria workers to improve drug distribution processes.
These changes resulted in a significant drop in parasite rates.
A flexible approach to MDA that takes into account the
unique, and constantly evolving, local patterns of human
movement, transmission dynamics, and vector populations
is essential.
All consulted experts saw DOT as a vital part of a delivery
strategy, and we found evidence that DOT using multiday
drug regimens is possible on a large scale. In the success-
ful campaigns, large populations were treated as small units.
For example, MPPT delivery teams were assigned groups
of approximately 200–250 people within a larger campaign
targeting populations in the tens of thousands to millions.8
Targeting small subgroups allowed for more efficient use
of limited resources, and facilitated safety monitoring
and achievement of coverage higher than 80%, a mini-
mum cutoff recommended by the consulted experts and
used in recent mathematical modeling research addressing
malaria elimination.22,23
Another significant finding was that community participa-
tion, understanding, and acceptance are essential for success.
In the countries where MPPT was implemented,8 obtaining
support of local authorities and cooperation of communities
was noted as key for ensuring good coverage and efficiency
of drug distribution. In the Solomon Islands, where great
efforts were made to educate and engage the community
using mass communication, investigators believed that MDA
failed because people were unwilling to take drugs on repeated
occasions when they were not sick. A more intense MDA
program in nearby Vanuatu, however, succeeded in inter-
rupting transmission when the community was engaged on a
more direct, interpersonal level.14 A clear understanding of
local culture, values, and community structure will improve
outreach and education efforts, thus increasing participation.
Despite inconsistent use of vector and larval control in the
reviewed studies, the vast majority of successful campaigns
used co-interventions to bring malaria incidence down to a
low level before attempting to interrupt transmission with
MDA, or both interventions were initiated simultaneously.
Although two of the 12 successful studies were able to achieve
zero transmission in some areas without implementing
co-interventions, one study author acknowledged that with-
out vector control, the population remained vulnerable to
future outbreaks arising from a residual parasite pool in
asymptomatic patients, or due to importation from neigh-
boring villages.13 The other study contained very limited
details, so contributing factors for the success of MDA in
the absence of vector control cannot be adequately assessed.18
Vector control is less of a priority in highly seasonal P. vivax
settings where there are regular periods of zero transmission
with no vectors present, but experts agreed that in other trans-
mission settings, every effort should be made to minimize
vector–human contact either prior to or concurrent with
MDA implementation. Vector control should be included
as a central part of an MDA strategy, particularly for
P. falciparum elimination in higher transmission areas.
Although millions of doses of primaquine have been dis-
tributed on a massive scale in several countries with minimal
adverse events reported, more safety data on both primaquine
and tafenoquine regimens are needed to support their wider
implementation as part of an elimination strategy.24,25 Past
studies did not document rigorous pharmacovigilance activities,
and it is very likely that adverse events were underreported.
Studies on the safety of primaquine in G6PD-replete and
G6PD-deficient populations are currently underway. Reassur-
ingly, a recently completed review of evidence derived from
previous studies involving 8-aminoquinolines by the WHO26
concluded that there is a very low risk of hemolysis among
subjects with mild or moderate G6PD deficiency when given
a single, low dose of primaquine. Safety studies among preg-
nant women are also needed, given the dearth of data on
pregnancy outcomes following primaquine administration. A
side study related to MDA conducted in the Gambia27,28 exam-
ined the safety of artesunate and pyrimethamine-sulfadoxine
in pregnancy and found no harmful effects; more studies using
the methodology applied in the Gambia are necessary.
In addition, more data on the most appropriate MDA drug
regimen are needed. The benefits of adding single, low-dose
primaquine for P. falciparum or single-dose tafenoquine to
ACTs for both P. falciparum and P. vivax need to be explored
through drug efficacy trials, as should the addition of other
potential anti-transmission agents, such as ivermectin and
methylene blue, and new drugs as they become available.3
The lessons and knowledge gaps summarized in this review
should be addressed through the establishment of a global
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research agenda, and in light of the current funding crisis
for health research, a pragmatic and efficient approach must
be taken. Differences in the efficacy of various drug regimens
are likely to have less of an impact on outcome than ensuring
high coverage29 during an MDA campaign; therefore, large-
scale trials should focus on optimal delivery strategies for
MDA, as well as the monitoring and evaluation of coverage,
cost-effectiveness, and impact in different endemicity settings.
Small-scale, highly controlled trials can be used to identify
the best MDA drug regimens and potential vector control
co-interventions for use in the larger trials. The target objec-
tives of the recommended MDA trials must be well defined
prior to implementation to bring much-needed clarity and
focus to this area of research.
Limitations. Although the research conducted for this
review was comprehensive, significant limitations exist. The
high variability of study methods and settings as well as the
poor quality of data derived from the published literature
pose major difficulties for analysis and the drawing of firm,
generalizable conclusions based on study results. Combining
the many and somewhat disparate forms of MDA into one
review may have introduced additional heterogeneity and
weakened the overall conclusions on effect and success of
MDA interventions. However, the more selective Cochrane
Review supports the findings of this review, and by includ-
ing a wider variety of studies along with input from MDA
experts, a broader assessment of factors such as delivery
strategies and size of target population could be carried out.
These experts provided valuable contextual insights based on
decades of institutional knowledge and personal experience
with MDA. Yet, their input cannot be treated in the same
manner as data derived from a rigorous published study, and
the experts we consulted tended to be biased in support of
MDA. In addition, not everyone who has experience with
MDA was interviewed, and the search for unpublished work
was not exhaustive, introducing reporting bias to these find-
ings. Publication bias was not formally assessed, but may
have influenced the review findings because malaria pro-
grams are less likely to publish studies with negative out-
comes and more likely to downplay adverse events. Finally,
the definition of success used to evaluate the published studies
is more applicable to P. falciparum than P. vivax. The 6-month
transmission-free period is not sufficient for assessing clear-
ance of hypnozoites, the dormant liver stage of P. vivax.
CONCLUSION
On the basis of the evidence presented here, MDA for
malaria should be designed and implemented with a long-
term view and a contextual, adaptable approach, drawing on
local knowledge and evidence as well as lessons learned from
previous MDA experiences. The historical successes described
in this review demonstrate that MDA can be used to reduce
and, in some circumstances, interrupt transmission of both
P. falciparum and P. vivax malaria in specific settings, and
should be considered for operational implementation as one
component of a comprehensive elimination strategy. In areas
with low transmission or seasonal P. vivax transmission, any
MDA strategies used should include close monitoring for cov-
erage, safety, and population impact on transmission rates.
In higher transmission areas, more research is likely needed
before MDA can be widely adopted, focusing particularly on
additional measures needed to maintain zero or low transmis-
sion following treatment rounds.
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